Tuesday, February 18, 2025

Light Horse Therapeutics Launches with $62 Million Series A Funding

Posted in
on
Light Horse Therapeutics Inc., a company focused on developing groundbreaking small molecule therapeutics, has secured $62 million in a Series A financing round led by Versant Ventures. The funding will support Light Horse’s unique “function-first” platform that identifies hidden functional sites on high-value protein targets, which diverges from traditional drug discovery methods by prioritizing function over screening. With an expert team including notable scientific co-founders and experienced executives, the company is advancing its preclinical programs, particularly in oncology, and has initiated a collaboration with Novartis. The innovative approach aims to uncover novel therapeutic targets, paving the way for new treatments in various disease areas.

Read More